Head-To-Head Comparison: Molecular Partners (MOLN) & Its Rivals

Molecular Partners (NASDAQ:MOLN) is one of 844 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Molecular Partners to related companies based on the strength of its earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Institutional & Insider Ownership

26.6% of Molecular Partners shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 5.9% of Molecular Partners shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and target prices for Molecular Partners and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Partners	1	1	2	0	2.25
Molecular Partners Competitors	9873	15286	45615	1598	2.54

Molecular Partners presently has a consensus price target of $8.38, suggesting a potential upside of 179.17%. As a group, “Biotechnology” companies have a potential upside of 125.25%. Given Molecular Partners’ higher probable upside, research analysts clearly believe Molecular Partners is more favorable than its competitors.

Earnings and Valuation

This table compares Molecular Partners and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Molecular Partners	$5.65 million	-$74.41 million	-1.79
Molecular Partners Competitors	$702.23 million	$9.48 million	-18.96

Molecular Partners’ competitors have higher revenue and earnings than Molecular Partners. Molecular Partners is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Molecular Partners has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500. Comparatively, Molecular Partners’ competitors have a beta of -1.84, indicating that their average share price is 284% less volatile than the S&P 500.

Profitability

This table compares Molecular Partners and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Molecular Partners	N/A	-80.03%	-62.56%
Molecular Partners Competitors	-12,323.33%	-195.91%	-30.60%

Summary

Molecular Partners competitors beat Molecular Partners on 8 of the 13 factors compared.

Molecular Partners Company Profile

Molecular Partners is a Swiss biotechnology company that develops protein-based medicines using its proprietary DARPin platform. Designed ankyrin repeat proteins, or DARPins, are engineered to bind specific biological targets and can be developed to act on one or several targets. The company’s research focuses on therapeutic candidates for cancer and other serious diseases. Its pipeline has included treatments designed to engage immune cells against tumors and to target proteins found in the tumor environment.